Ipsen Pharma: Ipsen receives its second Shingo Prize for operational excellence

• Ipsen is the first pharma company in the world to receive Shingo Prizes for two sites producing treatments for patients
• Ipsen's first Shingo Prize was received by its production site in Signes, France in 2020, followed by the site in Dublin, Ireland today
• The Shingo Prize represents the highest standard of operational excellence in the world

PARIS, FRANCE, 14 October 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its Dublin, Ireland production site has received the Shingo Prize for operational excellence. This is Ipsen's second Shingo Prize, with its site in Signes, France, receiving the first award in 2020.

Created in 1988, the Shingo Prize recognizes companies across all sectors that demonstrate a strong culture of operational excellence, deeply rooted in the mindset and behaviors of all staff, management and employees alike. This prestigious award is given to a maximum of five companies each year.

Ipsen's Dublin, Ireland site has almost 200 employees and produces the active pharmaceutical ingredients for two of Ipsen's medicines.

"It's truly an honor to receive this second Shingo Prize," said Aidan Murphy, Executive Vice-President, Head of Technical Operations, Ipsen. "Following the first prize our Signes site received in 2020, we immediately saw the impact of the Shingo mindset: every colleague understands how their work supports the strategy and focuses on continuous improvement and alignment between our values and behaviors. Bringing this level of excellence to our industrial and manufacturing footprint has allowed us to consistently deliver on our medicines and avoid shortages."

"I'm extremely proud of the people at Ipsen and their hard work that has created a fantastic culture at the Dublin site," said Paul Maginn, head of Excellence Enterprise and Manufacturing Science & Technology who played a pivotal role on the Shingo journey. "The Shingo Prize reflects the energy, dedication and commitment of each person to embedding the Shingo Model across the organization." Bénédicte Verley Hudry, Head of the Dublin site, said, "I had a remarkable experience during the Shingo assessment in Dublin. The Shingo Model emphasizes the importance of authentic engagement and dedication from all team members, and Dublin team truly embodies these principles."

ENDS

About Ipsen

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.

Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.

Ipsen contacts

Media

• Sam Howland | [phone] | [e-mail]
• Jennifer Smith-Parker | + 44 7843 137764 | [e-mail]

Disclaimers and/or Forward-Looking Statements

The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on ipsen.com.

Attachment

• Ipsen PR _ Shingo Gold Prize_14102024 (https://ml-eu.globenewswire.com/Resource/Download/6abe6c83-c23e-4d3c-8323-520ec88f827d)